{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:38:04Z","timestamp":1789706284974,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Tokushima University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jconrel.2015.10.019","type":"journal-article","created":{"date-parts":[[2015,10,18]],"date-time":"2015-10-18T04:35:26Z","timestamp":1445142926000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"PA","title":["Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed"],"prefix":"10.1016","volume":"220","author":[{"given":"Hidenori","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr S.","family":"Abu Lila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha Essam","family":"Eldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Ukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.10.019_bb0005","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0010","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-13-2062","article-title":"Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-met axis","volume":"74","author":"Menges","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0015","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/onc.2013.476","article-title":"Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma","volume":"33","author":"Cioce","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3892\/ijo.2013.2183","article-title":"AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma","volume":"44","author":"Sudo","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pneumo.2008.12.002","article-title":"First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma","volume":"65","author":"Burgin","year":"2009","journal-title":"Rev. Pneumol. Clin."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/01243894-200607000-00002","article-title":"i. Pemetrexed expanded access program, pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program","volume":"1","author":"Janne","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14737140.5.2.231","article-title":"Pemetrexed-cisplatin combination in mesothelioma","volume":"5","author":"Reck","year":"2005","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0040","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejcts.2009.08.012","article-title":"Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study","volume":"37","author":"Ampollini","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00595-005-3132-2","article-title":"Intrapleural hypotonic cisplatin treatment for malignant pleural mesothelioma: in vitro experiments and clinical application","volume":"36","author":"Tagawa","year":"2006","journal-title":"Surg. Today"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reynies","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0060","doi-asserted-by":"crossref","first-page":"7986","DOI":"10.1158\/1078-0432.CCR-04-1225","article-title":"Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA interference, on the activity of the new generation antifolate pemetrexed in HeLa cells","volume":"10","author":"Chattopadhyay","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0065","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1158\/1078-0432.CCR-04-0645","article-title":"Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier","volume":"10","author":"Wang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0070","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1158\/1078-0432.CCR-04-0932","article-title":"Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier","volume":"10","author":"Zhao","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0075","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1158\/0008-5472.CAN-03-3953","article-title":"Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway","volume":"64","author":"Zhao","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0080","first-page":"171","article-title":"Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions","volume":"7","author":"Monjanel-Mouterde","year":"2000","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0090","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.addr.2012.05.009","article-title":"Cationic lipids activate intracellular signaling pathways","volume":"64","author":"Lonez","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10717540490265243","article-title":"The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations","volume":"11","author":"Anderson","year":"2004","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0100","first-page":"1","article-title":"Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective managemente of malignant pleural mesothelioma","volume":"38","author":"Eldin","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0110","first-page":"91","article-title":"The removal of particulate matter from the pleura","volume":"42","author":"Karsner","year":"1920","journal-title":"J. Med. Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tips.2011.03.011","article-title":"Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma","volume":"32","author":"Favoni","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/138920010791110827","article-title":"Nanoparticles for tumor targeted therapies and their pharmacokinetics","volume":"11","author":"Wang","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0125","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1002\/jps.21358","article-title":"Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development","volume":"97","author":"Drummond","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcis.2004.05.042","article-title":"Mechanical properties and stability measurement of cholesterol-containing liposome on mica by atomic force microscopy","volume":"278","author":"Liang","year":"2004","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0135","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1021\/bi00011a042","article-title":"Effect of cholesterol, fatty acyl chain composition, and bilayer curvature on the interaction of cytochrome b5 with liposomes of phosphatidylcholines","volume":"34","author":"Taylor","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbamem.2004.03.006","article-title":"Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer","volume":"1663","author":"Charrois","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0145","first-page":"5922","article-title":"Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice","volume":"49","author":"Mayer","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0150","first-page":"2431","article-title":"Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine","volume":"52","author":"Allen","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00689270","article-title":"Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes","volume":"27","author":"Bally","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2014.12.038","article-title":"Augmented EPR effect by photo-triggered tumor vascular treatment improved therapeutic efficacy of liposomal paclitaxel in mice bearing tumors with low permeable vasculature","volume":"200","author":"Araki","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jconrel.2013.08.296","article-title":"Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes","volume":"172","author":"Stapleton","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","article-title":"Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects","volume":"63","author":"Maruyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.10.019_bb0180","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0169-5002(01)00278-1","article-title":"A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer","volume":"34","author":"Kim","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jconrel.2015.10.019_bb0185","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00001813-199911000-00007","article-title":"Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models","volume":"10","author":"Bandak","year":"1999","journal-title":"Anti-Cancer Drugs"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915301875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915301875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T15:02:58Z","timestamp":1572534178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915301875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":37,"alternative-id":["S0168365915301875"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.019","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}